Mutual of America Capital Management LLC Acquires 351 Shares of Glaukos Co. (NYSE:GKOS)

Mutual of America Capital Management LLC increased its holdings in shares of Glaukos Co. (NYSE:GKOSGet Rating) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,757 shares of the medical instruments supplier’s stock after purchasing an additional 351 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Glaukos were worth $391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Point72 Asset Management L.P. purchased a new stake in Glaukos during the fourth quarter valued at $29,779,000. Principal Financial Group Inc. purchased a new stake in Glaukos during the fourth quarter valued at $14,458,000. Assenagon Asset Management S.A. purchased a new stake in Glaukos during the fourth quarter valued at $11,325,000. D. E. Shaw & Co. Inc. increased its position in Glaukos by 175.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 250,058 shares of the medical instruments supplier’s stock valued at $11,113,000 after acquiring an additional 159,353 shares during the last quarter. Finally, Riverbridge Partners LLC increased its position in Glaukos by 14.2% during the first quarter. Riverbridge Partners LLC now owns 633,451 shares of the medical instruments supplier’s stock valued at $36,626,000 after acquiring an additional 78,896 shares during the last quarter. 92.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. BTIG Research upped their price objective on Glaukos from $61.00 to $66.00 in a research report on Monday, April 18th. Citigroup reduced their price target on Glaukos from $58.00 to $43.00 and set a “neutral” rating for the company in a research report on Tuesday, May 17th. Finally, Stifel Nicolaus upgraded Glaukos from a “hold” rating to a “buy” rating and upped their price target for the stock from $40.00 to $60.00 in a research report on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, Glaukos presently has an average rating of “Hold” and an average price target of $56.00.

Glaukos Stock Performance

NYSE:GKOS opened at $53.85 on Monday. The company has a current ratio of 8.84, a quick ratio of 8.39 and a debt-to-equity ratio of 0.59. Glaukos Co. has a 12-month low of $33.33 and a 12-month high of $64.49. The stock has a 50-day moving average price of $45.95 and a 200 day moving average price of $50.24. The stock has a market capitalization of $2.55 billion, a P/E ratio of -88.28 and a beta of 1.37.

Glaukos (NYSE:GKOSGet Rating) last released its earnings results on Wednesday, May 4th. The medical instruments supplier reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.14. Glaukos had a negative return on equity of 7.95% and a negative net margin of 9.45%. The firm had revenue of $67.70 million during the quarter, compared to analysts’ expectations of $60.85 million. During the same quarter last year, the business posted ($0.21) earnings per share. The firm’s revenue was down .4% on a year-over-year basis. Equities research analysts forecast that Glaukos Co. will post -1.78 EPS for the current fiscal year.

Glaukos Company Profile

(Get Rating)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Featured Stories

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOSGet Rating).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Want More Great Investing Ideas?

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.